BidaskClub upgraded shares of Quotient (NASDAQ:QTNT) from a sell rating to a hold rating in a report published on Tuesday morning.

Other research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Quotient from a hold rating to a buy rating in a report on Tuesday, August 28th. Zacks Investment Research raised shares of Quotient from a sell rating to a hold rating in a research note on Wednesday, October 10th.

NASDAQ QTNT opened at $6.48 on Tuesday. The stock has a market capitalization of $380.32 million, a PE ratio of -3.21 and a beta of 0.45. Quotient has a 12 month low of $2.78 and a 12 month high of $9.02.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.17). The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $5.80 million. On average, research analysts predict that Quotient will post -1.92 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in QTNT. Perceptive Advisors LLC lifted its stake in Quotient by 35.6% in the third quarter. Perceptive Advisors LLC now owns 8,789,054 shares of the company’s stock worth $66,357,000 after acquiring an additional 2,306,034 shares during the period. Highbridge Capital Management LLC lifted its stake in Quotient by 2,558.7% in the third quarter. Highbridge Capital Management LLC now owns 2,036,337 shares of the company’s stock worth $15,375,000 after acquiring an additional 1,959,746 shares during the period. Millennium Management LLC purchased a new stake in Quotient in the second quarter worth about $3,699,000. Bellevue Group AG lifted its stake in Quotient by 125.7% in the third quarter. Bellevue Group AG now owns 721,858 shares of the company’s stock worth $5,450,000 after acquiring an additional 402,044 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Quotient in the second quarter worth about $3,179,000. 53.75% of the stock is owned by institutional investors.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Recommended Story: What is intrinsic value?

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.